Metabolic liver disease in new HIV patients

This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.

This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.

This study examines blood and tissue samples from people with HIV, people without HIV, and healthy volunteers to understand how fatty liver disease develops and progresses. Researchers hope to find new ways to detect and treat fatty liver disease, especially in people living with HIV.

This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.

This study classifies fatty liver disease (MAFLD) by examining liver tissue samples. It aims to better understand how metabolic risk factors like high blood sugar, high blood pressure, or excess weight relate to the liver's condition.

This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.